Free. Unsubscribe any time.
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. filed 67 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 11 reporting owners, covering 106 transactions and 1,249,906 shares. None carries the SEC's AFF10B5ONE flag; all 67 name a plan in a footnote. 9 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-09-11, came 23 days after the one before it (2026-08-19) and reports 8 transactions against 9 in the filing before it.
- The sales it reports total 20,000 shares, 10,000 more than the 10,000 in the filing before it.
- Its 67 plan statements rank 2nd of the 10 companies the register carries in California, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 67 filings on file run from 2025-01-06 to 2026-09-11, and state no plan adoption date.
Trades in Travere Therapeutics, Inc. 106
- Inrig Jula — 2025-01-03 · S · 2,066 shares
- Inrig Jula — 2025-01-06 · S · 440 shares
- Dube Eric M — 2025-01-22 · S · 10,736 shares
- REED ELIZABETH E — 2025-01-22 · S · 2,437 shares
- ROTE WILLIAM E. — 2025-01-22 · S · 2,437 shares
- Baynes Roy D. — 2025-01-23 · S · 16,000 shares
- Dube Eric M — 2025-02-03 · S · 50,691 shares
- Inrig Jula — 2025-02-03 · S · 4,207 shares
- REED ELIZABETH E — 2025-02-03 · S · 8,951 shares
- ROTE WILLIAM E. — 2025-02-03 · S · 8,951 shares
- Inrig Jula — 2025-02-04 · S · 1,066 shares
- Baynes Roy D. — 2025-02-06 · S · 10,000 shares
Adoption dates in Travere Therapeutics, Inc. 0
Results prints in Travere Therapeutics, Inc. 9
- 2025-01-13
- 2025-02-20
- 2025-05-01
- 2025-08-06
- 2025-10-30
- 2026-01-12
- 2026-02-19
- 2026-05-04
- 2026-08-04
Trades before a print in Travere Therapeutics, Inc. 9
- 0 days before the 2026-05-04 print — 2026-05-04 · S · Inrig Jula · 20,000 shares
- 0 days before the 2026-05-04 print — 2026-05-04 · S · Meckler Jeffrey A · 8,000 shares
- 0 days before the 2026-05-04 print — 2026-05-04 · S · REED ELIZABETH E · 20,000 shares
- 1 day before the 2025-10-30 print — 2025-10-29 · S · Dube Eric M · 27,128 shares
- 2 days before the 2025-10-30 print — 2025-10-28 · S · Dube Eric M · 92,872 shares
- 2 days before the 2025-10-30 print — 2025-10-28 · S · Heerma Peter · 2,662 shares
- 2 days before the 2026-02-19 print — 2026-02-17 · S · REED ELIZABETH E · 5,679 shares
- 2 days before the 2026-02-19 print — 2026-02-17 · S · REED ELIZABETH E · 4,321 shares
- 3 days before the 2026-05-04 print — 2026-05-01 · S · Baynes Roy D. · 9,750 shares
- 6 days before the 2026-01-12 print — 2026-01-06 · S · Inrig Jula · 445 shares
- 7 days before the 2025-01-13 print — 2025-01-06 · S · Inrig Jula · 440 shares
- 7 days before the 2026-01-12 print — 2026-01-05 · S · Inrig Jula · 2,031 shares
Interval to Travere Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 9within 5 days
- 23within 10 days
- 0shortest, days
- 9no later print
- Inrig Jula 2025-01-03 · S · 10 days before the 2025-01-13 print · CHIEF MEDICAL OFFICER
- Inrig Jula 2025-01-06 · S · 7 days before the 2025-01-13 print · CHIEF MEDICAL OFFICER
- Calvin Sandra 2025-02-11 · S · 9 days before the 2025-02-20 print · SVP, CHIEF ACCOUNTING OFFICER
- Calvin Sandra 2025-02-11 · S · 9 days before the 2025-02-20 print · SVP, CHIEF ACCOUNTING OFFICER
- Calvin Sandra 2025-02-11 · S · 9 days before the 2025-02-20 print · SVP, CHIEF ACCOUNTING OFFICER
- Calvin Sandra 2025-02-11 · S · 9 days before the 2025-02-20 print · SVP, CHIEF ACCOUNTING OFFICER
- Calvin Sandra 2025-02-11 · S · 9 days before the 2025-02-20 print · SVP, CHIEF ACCOUNTING OFFICER
- Dube Eric M 2025-02-11 · S · 9 days before the 2025-02-20 print · CHIEF EXECUTIVE OFFICER
- Heerma Peter 2025-02-11 · S · 9 days before the 2025-02-20 print · CHIEF COMMERCIAL OFFICER
- Heerma Peter 2025-02-12 · S · 8 days before the 2025-02-20 print · CHIEF COMMERCIAL OFFICER
- REED ELIZABETH E 2025-02-12 · S · 8 days before the 2025-02-20 print · SVP, GC & CORPORATE SECRETARY
- ROTE WILLIAM E. 2025-02-12 · S · 8 days before the 2025-02-20 print · SENIOR VICE PRESIDENT, R&D
- Dube Eric M 2025-10-28 · S · 2 days before the 2025-10-30 print · CHIEF EXECUTIVE OFFICER
- Heerma Peter 2025-10-28 · S · 2 days before the 2025-10-30 print · CHIEF COMMERCIAL OFFICER
- Dube Eric M 2025-10-29 · S · 1 day before the 2025-10-30 print · CHIEF EXECUTIVE OFFICER
- Inrig Jula 2026-01-05 · S · 7 days before the 2026-01-12 print · CHIEF MEDICAL OFFICER
- Inrig Jula 2026-01-06 · S · 6 days before the 2026-01-12 print · CHIEF MEDICAL OFFICER
- REED ELIZABETH E 2026-02-17 · S · 2 days before the 2026-02-19 print · Chief Legal Officer and GC
- REED ELIZABETH E 2026-02-17 · S · 2 days before the 2026-02-19 print · Chief Legal Officer and GC
- Baynes Roy D. 2026-05-01 · S · 3 days before the 2026-05-04 print
Reported results dates on file
- 2025-01-13
- 2025-02-20
- 2025-05-01
- 2025-08-06
- 2025-10-30
- 2026-01-12
- 2026-02-19
- 2026-05-04
- 2026-08-04
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.